Solutions
Modelling and Simulation
Mechanism of Action Modelling
Exposure Response Modelling
Translational Modelling
Tumour Growth Inhibition Modelling
Population PK and NCA
PBPK Modelling
Clinical Trial Simulation
Biostatistics
Data Science & Bioinformatics
Virtual Tumour
Precision Oncology
Resources
Scientific Content
Investor Content
FAQs
News
All News
Investor News / RNS
Blog
Events
AIM Rule 26
Share Information
Investor News / RNS
Board of Directors
Advisors
Corporate Governance
Financial Reports
Corporate Documents
Registration
About Us
Partners
Team
Careers
Contact
Solutions
Modelling and Simulation
Mechanism of Action Modelling
Exposure Response Modelling
Translational Modelling
Tumour Growth Inhibition Modelling
Population PK and NCA
PBPK Modelling
Clinical Trial Simulation
Biostatistics
Data Science & Bioinformatics
Virtual Tumour
Precision Oncology
Resources
Scientific Content
Investor Content
FAQs
News
All News
Investor News / RNS
Blog
Events
AIM Rule 26
Share Information
Investor News / RNS
Board of Directors
Advisors
Corporate Governance
Financial Reports
Corporate Documents
Registration
About Us
Partners
Team
Careers
Contact
Solutions
Modelling and Simulation
Mechanism of Action Modelling
Exposure Response Modelling
Translational Modelling
Tumour Growth Inhibition Modelling
Population PK and NCA
PBPK Modelling
Clinical Trial Simulation
Biostatistics
Data Science & Bioinformatics
Virtual Tumour
Precision Oncology
Resources
Scientific Content
Investor Content
FAQs
News
All News
Investor News / RNS
Blog
Events
AIM Rule 26
Share Information
Investor News / RNS
Board of Directors
Advisors
Corporate Governance
Financial Reports
Corporate Documents
Registration
About Us
Partners
Team
Careers
Contact
10th March 2025 – Investor presentation – Company update
10th March 2025 – Investor presentation – Company update
Dr Peter Sargent, CEO
You Tube video of Physiomics Company update
Date
10th March 2025
Category
Investor
